Now showing items 1-2 of 2

    • Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. 

      Tutt, A; Tovey, H; Cheang, MCU; Kernaghan, S; Kilburn, L; Gazinska, P; Owen, J; Abraham, J; Barrett, S; Barrett-Lee, P; Brown, R; Chan, S; Dowsett, M; Flanagan, JM; Fox, L; Grigoriadis, A; Gutin, A; Harper-Wynne, C; Hatton, MQ; Hoadley, KA; Parikh, J; Parker, P; Perou, CM; Roylance, R; Shah, V; Shaw, A; Smith, IE; Timms, KM; Wardley, AM; Wilson, G; Gillett, C; Lanchbury, JS; Ashworth, A; Rahman, N; Harries, M; Ellis, P; Pinder, SE; Bliss, JM (2018-05)
      Germline mutations in BRCA1/2 predispose individuals to breast cancer (termed germline-mutated BRCA1/2 breast cancer, gBRCA-BC) by impairing homologous recombination (HR) and causing genomic instability. HR also repairs ...
    • International Cancer Microbiome Consortium consensus statement on the role of the human microbiome in carcinogenesis. 

      Scott, AJ; Alexander, JL; Merrifield, CA; Cunningham, D; Jobin, C; Brown, R; Alverdy, J; O'Keefe, SJ; Gaskins, HR; Teare, J; Yu, J; Hughes, DJ; Verstraelen, H; Burton, J; O'Toole, PW; Rosenberg, DW; Marchesi, JR; Kinross, JM (2019-09)
      OBJECTIVE:In this consensus statement, an international panel of experts deliver their opinions on key questions regarding the contribution of the human microbiome to carcinogenesis. DESIGN:International experts in oncology ...